tirzepatide approved for Unlikely to Exacerbate DR in First Year of Treatment In adults with obesity but

Related content Have Questions?

Tirzepatide programs may be discussed with eligible patients seeking medical weight-loss treatment

Glucagon-Like Peptide-1: A Multi-Faceted Anti-Inflammatory Agent

Briefly explained: What is an intrinsic factor

CDC summarizes that guidance directly in its injection safety recommendations: "Once a multi-dose vial is opened (e.g., needle-punctured) the vial should be dated and discarded within 28 days unless the manufacturer states another date for that opened vial

The Physician Perspective As a double board-certified internist and obesity-medicine specialist, I fully support advancing medical sciencebut only when its guided by rigorous research, regulatory oversight, and patient safety